Mitsubishi Tanabe Pharma Corporation

02/20/2024 | Press release | Distributed by Public on 02/20/2024 00:10

Application for Additional Dosage Form of CANALIA® Combination OD Tablets, Selective DPP-4 inhibitor/SGLT2 inhibitor Combination Drug